subjects completed a study Imatinib Glivec of darifenacin 24 months, 81% of solifenacin 40 weeks, a study has been completed, and 62% of subjects, a study tolterodine 12 months. Sw Chen Z They choose as a post-hoc analysis. Further Restrict Website will be the design of the open-label extension studies. This study is also subject to Restrict Website will for important papers used. For example, or in the field of sleep / energy of the KHQ m for may have not refl ect an improvement in symptoms To judge me OAB nocturia, and the scale for satisfaction with the treatment of n has not been validated. In addition, the Exclusion criteria included intercurrent illness and serious adverse events, which limits the applicability of our results for real populations. In addition, subjects Health Lebensqualit can t by Been changes in Komorbidit soldering and do not cover events in the life or questions about the 2-j YEAR OLD study period we have under the control or affected L. Schlie Lich had enrollment of patients in these studies, successful expansion completed 12 weeks of double-blind treatment and may therefore be more satisfied with treatment. Significantly cant improvements in the health-related Lebensqualit t and the severity of bladder problems even recorded, along with high satisfaction with the treatment that was observed in this study are consistent with the fi ndings of studies to evaluate the effects of short-term financial XED and fl exible dose fesoterodine treatment. Significant improvements in PRO cant Ma took Reported here are also compatible with the long-term improvement in symptoms of overactive bladder in these studies observed Verl EXTENSIONS. The fi ndings reported here are consistent with the results of health Lebensqualit t open in other studies to evaluate the beneficial long-term treatment of antimuscarinic reported. Overall, the results CCI-779 mTOR inhibitor of short-term trials and long-term extension this fesoterodine studies that fesoterodine is about the satisfaction with fesoterodine high and sustained over time and that treatment with fesoterodine is associated with each object u improvements in HRQOL, a relatively short period of time may agrees on up to 24 months of continuous therapy with M nnern and women and patients of various age groups, including normal older patients. Some aspects of health-related Lebensqualit t may gr Show Ere improve over time as patients more confidence tooth in the success of their treatment, with sustained improvements to, or obtained HRQL ht probably contribute to the achievement of long-term. The results of this meta-analysis of data from two open Verl show Ngerungsstudie studies that long-term treatment with once-t Resembled fesoterodine for overactive bladder with a clinically meaningful and statistically significant improvements in HRQOL is connected independently Ngig of gender or age . These favorable HRQL Haupts Chlich refl ECT with the long-term use of h Higher dose of fesoterodine. Subject honored throughout the treatment period of open treatment remained high in all groups. Hydrophilicity, such as quaternary Re amine trospium chloride, can be expected to have less CNS penetrance and cause less disruptions.